85
views
0
recommends
+1 Recommend
0 collections
    8
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      3D vena contracta area after MitraClip© procedure: precise quantification of residual mitral regurgitation and identification of prognostic information

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Percutaneous mitral valve repair (PMVR) is increasingly performed in patients with severe mitral regurgitation (MR). Post-procedural MR grading is challenging and an unsettled issue. We hypothesised that the direct planimetry of vena contracta area (VCA) by 3D–transoesophageal echocardiography allows quantifying post-procedural MR and implies further prognostic relevance missed by the usual ordinal scale (grade I-IV).

          Methods

          Based on a single-centre PMVR registry containing 102 patients, the association of VCA reduction and patients’ functional capacity measured as six-minute walk distance (6 MW) was evaluated. 3D–colour-Doppler datasets were available before, during and 4 weeks after PMVR.

          Results

          Twenty nine patients (age 77.0 ± 5.8 years) with advanced heart failure (75.9% NYHA III/IV) and severe degenerative (34%) or functional (66%) MR were eligible. VCA was reduced in all patients by PMVR (0.99 ± 0.46 cm 2 vs. 0.22 ± 0.15 cm 2, p < 0.0001). It remained stable after median time of 33 days ( p = 0.999). 6 MW improved after the procedure (257.5 ± 82.5 m vs. 295.7 ± 96.3 m, p < 0.01). Patients with a decrease in VCA less than the median VCA reduction showed a more distinct improvement in 6 MW than patients with better technical result ( p < 0.05). This paradoxical finding was driven by inferior results in very large functional MR.

          Conclusions

          VCA improves the evaluation of small residual MR. Its post-procedural values remain stable during a short-term follow-up and imply prognostic information for the patients’ physical improvement. VCA might contribute to a more substantiated estimation of treatment success in the heterogeneous functional MR group.

          Electronic supplementary material

          The online version of this article (10.1186/s12947-017-0120-9) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references36

          • Record: found
          • Abstract: found
          • Article: not found

          Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.

          Data on the effect of initial combination therapy with ambrisentan and tadalafil on long-term outcomes in patients with pulmonary arterial hypertension are scarce.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Percutaneous repair or surgery for mitral regurgitation.

            Mitral-valve repair can be accomplished with an investigational procedure that involves the percutaneous implantation of a clip that grasps and approximates the edges of the mitral leaflets at the origin of the regurgitant jet. We randomly assigned 279 patients with moderately severe or severe (grade 3+ or 4+) mitral regurgitation in a 2:1 ratio to undergo either percutaneous repair or conventional surgery for repair or replacement of the mitral valve. The primary composite end point for efficacy was freedom from death, from surgery for mitral-valve dysfunction, and from grade 3+ or 4+ mitral regurgitation at 12 months. The primary safety end point was a composite of major adverse events within 30 days. At 12 months, the rates of the primary end point for efficacy were 55% in the percutaneous-repair group and 73% in the surgery group (P=0.007). The respective rates of the components of the primary end point were as follows: death, 6% in each group; surgery for mitral-valve dysfunction, 20% versus 2%; and grade 3+ or 4+ mitral regurgitation, 21% versus 20%. Major adverse events occurred in 15% of patients in the percutaneous-repair group and 48% of patients in the surgery group at 30 days (P<0.001). At 12 months, both groups had improved left ventricular size, New York Heart Association functional class, and quality-of-life measures, as compared with baseline. Although percutaneous repair was less effective at reducing mitral regurgitation than conventional surgery, the procedure was associated with superior safety and similar improvements in clinical outcomes. (Funded by Abbott Vascular; EVEREST II ClinicalTrials.gov number, NCT00209274.).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Targeting Mitochondrial Calcium Handling and Reactive Oxygen Species in Heart Failure.

              In highly prevalent cardiac diseases, new therapeutic approaches are needed. Since the first description of oxidative stress in heart failure, reactive oxygen species (ROS) have been considered as attractive drug targets. Though clinical trials evaluating antioxidant vitamins as ROS-scavenging agents yielded neutral results in patients at cardiovascular risk, the knowledge of ROS as pathophysiological factors has considerably advanced in the past few years and led to novel treatment approaches. Here, we review recent new insights and current strategies in targeting mitochondrial calcium handling and ROS in heart failure.
                Bookmark

                Author and article information

                Contributors
                Alexander.dietl@ukr.de
                christine.prieschenk@ukr.de
                franziska.eckert@stud.uni-regensburg.de
                christoph.birner@ukr.de
                luchner.andreas@klinikum-amberg.de
                lars.maier@ukr.de
                stefan.buchner@ukr.de
                Journal
                Cardiovasc Ultrasound
                Cardiovasc Ultrasound
                Cardiovascular Ultrasound
                BioMed Central (London )
                1476-7120
                9 January 2018
                9 January 2018
                2018
                : 16
                : 1
                Affiliations
                [1 ]ISNI 0000 0000 9194 7179, GRID grid.411941.8, Department of Internal Medicine II, , University Hospital Regensburg, ; Franz-Josef-Strauss Allee 11, D-93053 Regensburg, Germany
                [2 ]ISNI 0000 0001 1958 8658, GRID grid.8379.5, Comprehensive Heart Failure Center Würzburg, , University Hospital and University of Würzburg, ; Würzburg, Germany
                [3 ]Department of Internal Medicine I, Klinikum St. Marien, Amberg, Germany
                [4 ]Department of Internal Medicine II, Sana Kliniken Cham, Cham, Germany
                Author information
                http://orcid.org/0000-0002-4091-8620
                Article
                120
                10.1186/s12947-017-0120-9
                5759791
                29310672
                da18426e-b061-404d-92e9-dd00748d60cb
                © The Author(s). 2018

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 19 September 2017
                : 19 December 2017
                Funding
                Funded by: DGK - Deutsche Gesellschaft für Kardiologie
                Categories
                Research
                Custom metadata
                © The Author(s) 2018

                Cardiovascular Medicine
                percutaneous mitral valve repair,mitraclip,3d echocardiography,vena contracta area,six-minute walk test,nt-probnp,prognosis,functional mitral regurgitation

                Comments

                Comment on this article